Abstract
The efficacy and safety of bepotastine besilate (Talion®) in the treatment of chronic urticaria were evaluated in 88 adult patients with chronic urticaria. Patients were openly treated with 20 mg/day oral bepotastine besilate for 14 days. Clinical evaluations were performed every 7 days, and patients were asked to keep a diary, recording their pruritus scores. Symptoms improved in 77.1% of the patients after two weeks and pruritus scores were reduced significantly within 24 h after oral administration in 69.6% of patients. It appears that bepotastine besilate can be ranked as a drug of first choice for the treatment of chronic urticaria, because it rapidly relieved itch and the incidence of drowsiness was relatively low.
